INDIANAPOLIS -- (August 12, 2013) -- Indiana University physician scientist Lawrence H. Einhorn, M.D., has been named one of the 2013 “Giants of Cancer Care” by OncLive for developing the lifesaving treatment for testicular cancer.
Dr. Einhorn, Indiana University Distinguished Professor and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, is one of 12 luminaries nationwide selected by oncology industry peers for his remarkable achievements in research or clinical practice.
He is widely recognized for developing in 1974 a chemotherapy regimen for testicular cancer that revolutionized therapy and is responsible for a dramatic improvement in the cure rate of what previously had been a devastating and rapidly fatal disease. Today, more than 95 percent of all patients with this disease now survive. The survival rate for testicular patients who develop metastatic disease is now 80 percent, up from 10 percent prior to Dr. Einhorn’s revolutionary therapy.
“Dr. Lawrence Einhorn has been a giant in the field of oncology,” said Dr. Corey Langer, a professor of medicine at Abramson Cancer Center at the University of Pennsylvania, and an advisory panel member for the Giants of Cancer Care program. “He helped turn metastatic testicular cancer, a nearly always fatal malignancy, into a curable entity, harnessing the power of combination, platinum-based chemotherapy, and teaching us how to discipline its toxicities. Thousands of adult men in the United States and around the world owe their survival to Dr. Einhorn and his colleagues.”
Dr. Einhorn’s clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers.
Dr. Einhorn has published more than 450 peer-reviewed articles. He has received the most prestigious awards of the American Association for Cancer Research (Richard and Hinda Rosenthal Award) and of the American Society of Clinical Oncology (Karnofsky Award), as well as the American Cancer Society Medal of Honor, and the General Motors Kettering Prize. He is a member of the National Academy of Sciences and American Philosophical Society, the oldest learned society in the United States that promotes scholarly research in the sciences and humanities.
The inaugural Giants of Cancer Care awards recognize and celebrate individuals who have achieved landmark success within the field of oncology. Giants are organized by specialty and chosen by an exclusive advisory panel of oncology educators, clinicians and researchers.
In evaluating criteria for selection to the inaugural class of giants, the advisory panel considered “pioneers,” characterized by individuals who have amassed a large body of work and have already accomplished their most notable contributions to oncology; and separately, “innovators,” those who recently have made a significant contribution to patient care, clinical trials, or translational research.
OncLive Chairman and CEO Mike Hennessy said, “We’re proud to honor these exemplary members of the oncology profession. These ‘Giants’ have dedicated their lives to improving the quality and quantity of life for cancer patients. Our enormous gratitude is the foundation of this program.”
The 2013 Giants of Cancer Care recently were honored at a reception in Huntington Beach, Calif. Each giant will be individually profiled in a November 2013 special edition of OncologyLive.
###
About OncLive
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Urologists in Cancer Care, Oncology Nursing News and Contemporary Oncology. The mission of OncLive and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research and education.
